New drug combo may protect bones after spinal cord injury

NCT ID NCT05101018

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 4 trial tests whether starting with romosozumab for 12 months and then switching to denosumab for another 12 months can better maintain bone density around the knee in people with recent spinal cord injury, compared to using denosumab alone. The study involves 40 adults aged 18-55 who have had a spinal cord injury for less than 6 months. Researchers will measure bone mineral density using X-ray scans to see which approach works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Romosozumab (Evenity) and Denosumab (Prolia)
What this could lead to
If successful, this could point toward a better treatment sequence to prevent severe bone loss and fractures after spinal cord injury.
What could go wrong
This is a small early-phase trial with only 40 participants, so results may not apply to everyone. Romosozumab carries heart risks, and the study excludes people with heart disease or stroke history.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • James J. Peters VA Medical Center

    The Bronx, New York, 10468, United States

  • Kessler Institute for Rehabilitation

    West Orange, New Jersey, 07052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.